LOGIN  |  REGISTER

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Vertex Pharmaceuticals and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment...

December 8
Last Trade: 350.15 -3.80 -1.07

First-ever approval of a CRISPR-based gene-editing therapy in the U.S. Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment Multiple authorized treatment centers activated BOSTON & ZUG, Switzerland / Dec...Read more


CRISPR Therapeutics and Vertex Pharmaceuticals Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment...

December 8
Last Trade: 64.54 -5.67 -8.08

First-ever approval of a CRISPR-based gene-editing therapy in the U.S. Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment Multiple authorized treatment centers activated BOSTON & ZUG, Switzerland / Dec...Read more


bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell...

December 8
Last Trade: 2.86 -1.95 -40.54

Severe vaso-occlusive events were eliminated for 94% (30/32) of evaluable patients and all VOEs were eliminated for 88% (28/32) of evaluable patients between 6 and 18 months post-infusion LYFGENIA is the most deeply studied gene therapy for sickle cell disease with the most patients treated and...Read more


FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Genentech’s Kadcyla Is First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive...

December 8
Last Trade: 36.00 0.42 1.18

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study These data...Read more


Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line...

December 8
Last Trade: 103.75 -0.13 -0.13

RAHWAY, N.J., & NUTLEY, N.J. / Dec 08, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple...Read more


Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic...

December 8
Last Trade: 120.42 0.87 0.73

First presentation of progression-free survival (PFS) primary endpoint data show zanidatamab plus palbociclib and fulvestrant demonstrated a PFS of 67% at 6 months and a median PFS of 12 months in patients with heavily pre-treated HER2+/HR+ metastatic breast cancer (mBC) Efficacy and...Read more


Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Eli Lilly 9.78 1.66 $598.05
IDEXX Laboratories 8.27 1.58 $531.35
Instil Bio 6.35 2,012.77 $6.67
Lantheus 5.18 7.56 $73.71
Science 37 4.69 1,954.17 $4.93
Align Technology 4.62 2.13 $221.23
Molina Healthcare 4.29 1.18 $367.72
ICON 4.27 1.59 $272.46
Inspire Medical Systems 4.19 2.60 $165.09
Cassava Sciences 3.61 17.37 $24.39
HCA Healthcare 3.58 1.41 $257.53
Krystal Biotech 3.46 3.35 $106.86
Disc Medicine 3.44 5.98 $61.01
Univerl Health Services 3.10 2.31 $137.45
ALX Oncology 3.01 32.54 $12.26
Intensity Therapeutics 2.88 72.00 $6.88
Zoetis 2.77 1.52 $184.60

Highest Volume

 
CompanyVolumeLast Trade
Therapeutic Solutions 52,864,999 $0.001
bluebird bio 51,855,597 $2.86
Intensity Therapeutics 31,734,433 $6.88
Altimmune 27,841,585 $6.48
Pfizer 27,714,307 $28.78
Exicure 24,620,017 $0.52
Ginkgo Bioworks 17,811,279 $1.36
Walgreens Boots Alliance 17,214,657 $23.16
CRISPR Therapeutics 17,132,757 $64.54
Avalo Therapeutics 14,463,872 $0.05
eFFECTOR Therapeutics 14,024,760 $0.52
ImmunoGen 13,496,602 $29.21
Bristol-Myers Squibb 10,107,566 $50.31
Altamira Therapeutics 9,385,806 $0.41
Veradigm 8,734,270 $10.07
CVS Health 8,677,714 $75.10
Elanco Animal Health 8,619,100 $12.80
  • Upcoming FDA Catalysts

    • Cellectis (NASDAQ: CLLS) Data Presentation

      December 9, 2023
    • BioAtla (NASDAQ: BCAB) Data Presentation

      December 13, 2023
    • bluebird bio (NASDAQ: BLUE) PDUFA Date

      December 20, 2023
    • Calliditas Therapeutics (NASDAQ: CALT) PDUFA Date

      December 20, 2023
    • Calliditas Therapeutics (NASDAQ: CALT) PDUFA Date

      December 20, 2023
    • Ionis Pharmaceuticals (NASDAQ: IONS) PDUFA Date

      December 22, 2023

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities:
Edit

COPYRIGHT ©2023 HEALTH STOCKS HUB